GERRESHEIMER AG

Gerresheimer AG shifts voting‑rights after US consortium stake move – discover what this could mean for its strategy, governance, and stock outlook.

Gerresheimer AG: a resilient life‑science supplier poised for double‑digit growth in injectable & biologic packaging—current dip may signal a long‑term value play.

Gerresheimer AG discloses a voting‑rights announcement and a short‑sale position, revealing recent shareholder activity and market sentiment in the life‑sciences sector.

Gerresheimer AG’s stock is under intense short‑selling pressure, revealing market doubts and volatility; explore why investors are watching this healthcare player.

Gerresheimer AG’s plunge: accounting scandals, debt restructuring, and a rejected €41 takeover bid leave investors wary, showing how missteps erode value.

Gerresheimer AG faces investor uncertainty after delayed 2025 reports, a postponed shareholder meeting, credit talks, and the sale of its U.S. unit—yet its specialty glass business still holds long‑term growth potential.

Gerresheimer AG Aktie sinkt um 3 % nach Berichtverschiebung: Analysten senken Kursziele, „Hold"-Bewertung bleibt – jetzt potenziell unterbewertet?

Gerresheimer AG’s shares appear “stable” after Oddo’s nod, yet tariff worries, a weak SDAX and rising short‑selling hint at hidden volatility. Discover how to navigate this uncertain outlook for the pharma‑packaging specialist.

Gerresheimer AG corrects 2024 earnings after BaFin flags Bill‑and‑Hold revenue misstatement, cutting earnings per share and prompting a sharp stock drop.

Gerresheimer AG revises 2024 earnings by €28 m after BaFin audit, yet shares stay steady and a Buy rating is maintained.